Loading…
Reported covered position: 2005-2011 Senate HELP Cmte; Dir. of Oversight2003-2004 Senate Budget Committee2001-2002 Ofc. of Asst. GOP Leader Sen. Nickles
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2026 · third_quarter · Q3
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Source: Senate LDA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
SAFE Drugs Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
SAFE Drugs Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
CLEAR LABELS Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2026
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
SAFE Drugs Act of 2026
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
SAFE Drugs Act of 2026
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Drug Shortage Compounding Patient Access Act of 2025
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Safer Compounding in Hospitals Act of 2024
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Safer Compounding in Hospitals Act of 2024
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications
Patient Access to Urgent-Use Pharmacy Compounding Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Drug Origin Transparency Act of 2023
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Patient Access to Urgent-Use Pharmacy Compounding Act of 2021
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Preserving Patient Access to Compounded Medications Act of 2019
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017; Issues related to opioid safety
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017; Issues related to opioid safety
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017; Issues related to opioid safety
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
Preserving Patient Access to Compounded Medications Act of 2017
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Drug Quality and Security Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Pharmaceutical Compounding Quality and Accountability Act; The Compounding Clarity Act; Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Drug Quality and Security Act
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Agricultural Appropriations Spending Bill (HR 4800/S2389)
Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2015
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Agricultural Appropriations Spending Bill (HR 4800/S2389)
Ensuring Safe Access to Prescription Medication Act of 2014
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Ensuring Safe Access to Prescription Medication Act of 2014
Client: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA · Firm: PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
Pharmaceutical Compounding Quality and Accountability Act; The Compounding Clarity Act; Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2026 · second_quarter · Q2
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788/ H.R. 8269 The Clear Labels Act
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2026 · first_quarter · Q1
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025; S. 3794 / H.R. 6509, The Safe Drugs Act; S. 3788, The Clear Labels Act
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2025 · fourth_quarter · Q4
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2025 · third_quarter · Q3
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 5316, the Drug Shortage Compounding Patient Access Act of 2025
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2025 · second_quarter · Q2
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2025 · first_quarter · Q1
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2024 · fourth_quarter · Q4
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2024 · third_quarter · Q3
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023; H.R. 8749, Safer Compounding in Hospitals Act
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2024 · second_quarter · Q2
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2024 · first_quarter · Q1
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2023 · fourth_quarter · Q4
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2023 · third_quarter · Q3
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees; H.R. 3810 - Drug Origin Transparency Act of 2023
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications; H.R. 3810 - Drug Origin Transparency Act of 2023
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2023 · second_quarter · Q2
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2023 · first_quarter · Q1
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 167, the Patient Access to Urgent Use Pharmacy Compounding Act of 2023; patient access to compounded medications
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2022 · fourth_quarter · Q4
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2022 · third_quarter · Q3
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Agriculture appropriations spending bill.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2022 · second_quarter · Q2
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Agriculture appropriations spending bill.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2022 · first_quarter · Q1
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Agriculture appropriations spending bill.
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2021 · fourth_quarter · Q4
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Agriculture appropriations spending bill.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2021 · third_quarter · Q3
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; patient access to compounded medications.
Agriculture appropriations spending bill.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2021 · second_quarter · Q2
Agriculture appropriations spending bill.
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021.
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2021 · first_quarter · Q1
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Agriculture appropriations spending bill.
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2020 · fourth_quarter · Q4
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Agriculture appropriations spending bill.
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2020 · third_quarter · Q3
Agriculture appropriations spending bill.
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2020 · second_quarter · Q2
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain; issues related to drug shortages
Agriculture appropriations spending bill.
Issues related to Medicare coverage of compounded medications, Drug shortages and Medicare reimbursement for compounded medications, pharmacy direct and indirect remuneration fees.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2020 · first_quarter · Q1
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety; issues related to the pharmaceutical supply chain
Issues related to Medicare coverage of compounded medications, pharmacy direct and indirect remuneration fees.
Agriculture appropriations spending bill.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2019 · fourth_quarter · Q4
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Agriculture appropriations spending bill.
Issues related to Medicare coverage of compounded medications, pharmacy direct and indirect remuneration fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2019 · third_quarter · Q3
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Agriculture appropriations spending bill.
Issues related to Medicare coverage of compounded medications, pharmacy direct and indirect remuneration fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2019 · second_quarter · Q2
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Agriculture appropriations spending bill.
Issues related to Medicare coverage of compounded medications, pharmacy direct and indirect remuneration fees.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2019 · first_quarter · Q1
Issues related to implementation of the Drug Quality and Security Act, issues related to animal drug compounding, H.R. 1959 The Preserving Patient Access to Compounded Medications Act of 2019, issues relating to opioid safety.
Issues related to Medicare coverage of compounded medications, pharmacy direct and indirect remuneration fees.
Agriculture appropriations spending bill.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2018 · fourth_quarter · Q4
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017; Issues related to opioid safety
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2018 · third_quarter · Q3
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017; Issues related to opioid safety
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2018 · second_quarter · Q2
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017; Issues related to opioid safety
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2018 · first_quarter · Q1
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2017 · fourth_quarter · Q4
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2017 · third_quarter · 3A
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2017 · third_quarter · Q3
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding; H.R. 2871, the Preserving Patient Access to Compounded Medications Act of 2017.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2017 · second_quarter · Q2
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2017 · first_quarter · Q1
Issues related to FDA implementation of The Drug Quality and Security Act; issues related to animal drug compounding
Agricultural Appropriations Spending Bill, specifically FDA funding for and implementation of the Drug Quality and Security Act. Issues related to animal drug compounding.
Issues related to Medicare coverage of compounded medications. S 413 Improving Transparency and Accuracy in Medicare Part D Spending Act
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2016 · fourth_quarter · Q4
Issues related to Medicare coverage of compounded medications.
TriCare benefit issues.
TriCare benefit issues; Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2016 · third_quarter · Q3
TriCare benefit issues.
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).
TriCare benefit issues; Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2016 · second_quarter · Q2
TriCare benefit issues.
TriCare benefit issues; Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2016 · first_quarter · Q1
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).
Issues related to Medicare coverage of compounded medications.
TriCare benefit issues.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2015 · fourth_quarter · Q4
Issues related to Medicare coverage of compounded medications.
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).
TriCare benefit issues.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2015 · third_quarter · Q3
Issues related to Medicare coverage of compounded medications.
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).
Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2015 · second_quarter · Q2
TriCare benefit issues
Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act
Issues related to Medicare coverage of compounded medications
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2015 · first_quarter · Q1
TriCare benefit issues
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014
Issues related to Medicare coverage of compounded medications
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2014 · fourth_quarter · Q4
Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Agricultural Appropriations Spending Bill (HR 4800/S2389)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2014 · third_quarter · Q3
Pharmaceutical Compounding Quality and Accountability Act; The Compounding Clarity Act; Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825)
Agricultural Appropriations Spending Bill (HR 4800/S2389)
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PROFESSIONAL COMPOUNDING CENTERS OF AMERICA via PROFESSIONAL COMPOUNDING CENTERS OF AMERICA
2014 · third_quarter · RR
Compounding pharmacy and FDA issues; FDA funding
Compounding pharmacy and FDA issues; FDA funding
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Agriculture appropriations spending bill; Department of Labor-Health and Human Services appropriations bill
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Issues related to FDA implementation of The Drug Quality and Security Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406).
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare coverage of compounded medications.
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to Medicare coverage of compounded medications.
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act.
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
TriCare benefit issues.
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Issues related to FDA implementation of The Drug Quality and Security Act Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014; issues related to animal drug compounding; Saving Access to Compounded Medications for Special Needs Patients Act (S/1406);
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
Agricultural Appropriations Spending Bill, specifically FDA funding for implementation of the Drug Quality and Security Act
Filing targets: Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE